Zhu, Jian <br/><br/>
DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.  [electronic resource] 

 -  Journal of experimental & clinical cancer research : CR  Sep 2012 
 - 80 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1756-9966 
<br/><br/><label>Standard No.: </label>10.1186/1756-9966-31-80  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adaptor Proteins, Signal Transducing<br/>Aged<br/>Biomarkers, Pharmacological<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>DNA Methylation--genetics<br/>Disease-Free Survival<br/>ErbB Receptors--antagonists & inhibitors<br/>Eye Proteins--genetics<br/>Female<br/>Humans<br/>Male<br/>Membrane Proteins--genetics<br/>Middle Aged<br/>Mutation<br/>Neoplasm Staging<br/>Protein Kinase Inhibitors--administration & dosage<br/>Treatment Outcome<br/>Wnt Signaling Pathway